Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REDUCE PMR rituximab trial in newly diagnosed polymyalgia rheumatica
NL-OMON60175Phase 4Completed
- Sponsor
- Sint Maartenskliniek
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in polymyalgia rheumatica (PMR) comparing rituximab with placebo (2 arms). Primary endpoint: Glucocorticoid-free remission at 1 year. Started Feb 2023; status: completed.
02
Drugs
rituximab
03
Conditions
polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on NL-OMON60175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60175.